Theophylline Extended-Release Tablets

[13 January 2017]

Products Affected - Description

Theophylline extended release tablet, Teva
100 mg, bottle, 100 count (NDC 50111-0483-01)
100 mg, bottle, 500 count (NDC 50111-0483-02)
200 mg, bottle, 100 count (NDC 50111-0482-01)
200 mg, bottle, 500 count (NDC 50111-0482-02)
200 mg, bottle, 1000 count (NDC 50111-0482-03)
300 mg, bottle, 100 count (NDC 50111-0459-01)
300 mg, bottle, 500 count (NDC 50111-0459-02)
300 mg, bottle, 1000 count (NDC 50111-0459-03)

Reason for the Shortage

  • Major has discontinued theophylline extended-release tablets.
  • Teva cannot provide a reason for the shortage.

Available Products

There are no presentations available.

Estimated Resupply Dates

Teva has theophylline extended-release tablets temporarily unavailable and the company cannot estimate a release date.

Related Shortages


January 13, 2017; October 19, August 15, July 20, June 9, May 13, April 14, February 5, 2016; December 16, 2015, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing